Vascular disease meta analyses

A single patient’s medical records, combined with thousands of others from multiple trials, are being re-analysed to settle long-running disputes about common heart and stroke treatments. The problem is that individual clinical trials are often too small to detect rare side effects or to show whether a drug works differently in men versus women, older versus younger patients, or those with other health conditions. Standard meta-analyses, which pool only the published summaries from each trial, miss this detail. This research group instead obtains the raw, individual-level data from every participant in every relevant trial—a far more labour-intensive approach—and then re-analyses the combined dataset to answer questions that single trials cannot. If successful, this work could settle unresolved safety questions that affect millions of people. For example, it will clarify whether statins actually cause muscle pain (a common reason patients stop taking them), whether the clot-busting drug alteplase benefits specific stroke patients more than others, and whether low-dose aspirin is worth the bleeding risk for healthy people considering it for prevention. It will also determine whether angiotensin-receptor blockers slow aortic enlargement in Marfan syndrome, potentially changing surgical timing for patients with that condition. The results will directly inform prescribing guidelines and clinical decisions worldwide.